Tentative identification of phase I metabolites of HU-210, a classical synthetic cannabinoid, by LC-MS/MS
- Authors
- Kim, Unyong; Jin, Ming Ji; Lee, Jaeick; Han, Sang Beom; In, Moon Kyo; Yoo, Hye Hyun
- Issue Date
- May-2012
- Publisher
- Elsevier BV
- Keywords
- HU-210; Synthetic cannabinoid; Metabolism; LC-MS/MS
- Citation
- Journal of Pharmaceutical and Biomedical Analysis, v.64-65, pp.26 - 34
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Pharmaceutical and Biomedical Analysis
- Volume
- 64-65
- Start Page
- 26
- End Page
- 34
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/33051
- DOI
- 10.1016/j.jpba.2012.02.007
- ISSN
- 0731-7085
- Abstract
- (6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210) is a synthetic cannabinoid, with a classical cannabinoid structure similar to Delta(9)-tetrahydrocannabinol (Delta(9)-THC). In this study, the in vitro metabolism of HU-210 was investigated in human liver microsomes to characterize associated phase I metabolites. HU-210 was incubated with human liver microsomes, and the reaction mixture was analyzed using LC-MS/MS. HU-210 was metabolized in human liver microsomes, yielding about 24 metabolites. These metabolites were structurally characterized on the basis of accurate mass analyses and MS/MS fragmentation patterns. The major metabolic route for HU-210 was oxygenation. Metabolites M1-M7 were identified as mono-oxygenated metabolites; MB-M15, mono-hydroxylated metabolites; M16-M20, di-oxygenated metabolites; and M21-M24, di-hydroxylated metabolites. These results provide evidence for in vivo HU-210 metabolism, and they may be applied to the analysis of HU-210 and its relevant metabolites in biological samples. (C) 2012 Elsevier B.V. All rights reserved.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.